Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$73.43 USD

73.43
684,127

+0.80 (1.10%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $73.40 -0.03 (-0.04%) 6:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip

According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.

Here's What Key Metrics Tell Us About Globus Medical (GMED) Q2 Earnings

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 5% and 3.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Gains on Innovation, Strategic Deal

Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.

ITGR or GMED: Which Is the Better Value Stock Right Now?

ITGR vs. GMED: Which Stock Is the Better Value Option?

Here's Why You Should Retain Globus Medical (GMED) Stock Now

New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.

Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe

Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.

Globus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 3.92% and 8.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 3.28% and 10.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Globus' (GMED) NUVA Buyout Seems Strategic, Cost Woe Stays

Globus Medical (GMED) and NuVasive (NUVA) are currently planning to combine in an all-stock transaction to create a global musculoskeletal company.

Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs

The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.

NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth

According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.

Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises

Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.

Globus Medical (GMED) Tops Q4 Earnings Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 7.27% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Q4 Earnings and Revenues Surpass Estimates

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 274.75% and 1.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Lags Q3 Earnings and Revenue Estimates

Steris (STE) delivered earnings and revenue surprises of -9.01% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why Investors Should Retain Globus Medical (GMED) Stock

Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.

Globus Medical (GMED) Global Growth Strong Despite Margin Woe

Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.

Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut

Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.